Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
52W High
$26.65
52W Low
$13.40
MA Status:
50D: Above
200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.75
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
17.89
Forward P/E (<15 better)
23.09
EV/EBITDA (<8 favorable)
31.83
EV/Revenue (<3 favorable)
3.25
P/S (TTM) (<3 favorable)
3.94
P/B (<3 favorable)
4.88
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
0.55%
Institutions (25–75% balanced)
103.22%
Shares Outstanding
168,712,000
Float
115,870,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,018,885,000
Gross Profit (TTM)
613,546,000
EPS (TTM)
1.33
Profit Margin (>10% good)
0.22%
Operating Margin (TTM) (higher better)
0.12%
ROE (TTM) (>15% strong)
0.33%
EPS YoY (Quarterly) (>10% good)
-0.21
Revenue YoY (Quarterly) (>8% good)
0.09
Momentum
Bearish momentumValue
-0.0295
Previous
0.1237
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025